# Regenerative Medicine for Joint Hypermobility and Instability

> **NCT07688096** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Manhattan Pain Medicine, PLLC** · enrollment: 100 (estimated)

## Conditions studied

- Ehlers-Danlos Syndrome Hypermobility Type (hEDS)
- Ehlers-Danlos Syndrome (EDS)
- Joint Hypermobility
- Joint Instability
- Hypermobility Spectrum Disorder
- Chronic Pain Syndrome
- Musculoskeletal Pain
- Sprain
- Subluxation
- Dislocation
- Craniocervical Disfunction

## Interventions

- **DRUG:** Dextrose 20% Prolotherapy
- **BIOLOGICAL:** Autologous Platelet-Rich Plasma
- **DRUG:** Doxycycline Hyclate Injectable (Investigational)
- **DEVICE:** Visco-3 Sodium Hyaluronate Viscosupplementation

## Key facts

- **NCT ID:** NCT07688096
- **Lead sponsor:** Manhattan Pain Medicine, PLLC
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2027-01-15
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07688096

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07688096, "Regenerative Medicine for Joint Hypermobility and Instability". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07688096. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*